Press Releases
|
August 29, 2022

Zerion Pharma and Insud Pharma announce collaboration to develop Dispersome® formulations of marketed drug products

AUGUST 29, 2022 (COPENHAGEN, Denmark). The Danish pharmaceutical company Zerion Pharma A/S (ZERION) and the Spanish pharmaceutical group Insud Pharma, SL today are announcing their collaboration to develop

Press Releases
|
August 23, 2022

Zerion Pharma and Hovione extend partnership to cover use of the Dispersome® technology platform in nutraceuticals

AUGUST 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION) and Hovione today announced an extension of their collaboration on ZERION’s Dispersome® technology into the nutraceutical/dietary supplements field.

Press Releases
|
February 23, 2022

Arla Foods Ingredients and Zerion Pharma complete long-term supply agreement for beta-lactoglobulin (Lacprodan® BLG-100)

February 23, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (“ZERION”) announces today that it has executed a long-term agreement with Arla Foods Ingredients covering the supply of its Lacprodan® BLG-100 for use as

Press Releases
|
February 22, 2022

Zerion Pharma and Hovione form strategic partnership to market and commercialise the proprietary Dispersome® technology platform

February 22, 2022 (COPENHAGEN, Denmark). Zerion Pharma A/S (ZERION), a Danish drug development company, is pleased to announce today to have entered into a strategic partnership with HOVIONE, a leading global specia

Press Releases
|
January 10, 2022

New study shows that the amount of active drug in cancer tablets may be reduced by 75% using the Dispersome® technology

January 10, 2022 (COPENHAGEN, Denmark). The Danish drug development company, Zerion Pharma A/S (ZERION) has completed a new animal study (in dogs) that clearly demonstrates the potential of its patented Dispersome®

Press Releases
|
December 21, 2021

Zerion Pharma elects Dr. Dorte Arnbjerg as a new board member

(Copenhagen, December 21, 2021). ZERION Pharma A/S, a Danish pharmaceutical company, elected Dr. Dorte Arnbjerg to join its board of directors at an extraordinary general meeting held on December 14, 2021. 

Press Releases
|
November 24, 2021

Zerion Pharma ApS extends its licensing agreement with Rousselot B.V to exploit Dispersome® technology platform

24 November, 2021 (COPENHAGEN, Denmark). Rousselot B.V. and Zerion Pharma ApS announce today that they have strengthened their partnership through an extension of

Press Releases
|
May 10, 2021

ZERION PHARMA elects Dr. Torsten Goesch and Dr. Lars Lykke Thomsen as new board members

(Copenhagen, May 10, 2021). ZERION Pharma, a Danish pharmaceutical company, elected two new members Dr. Torsten Goesch and Dr. Lars Lykke Thomsen to join its board of directors at the annual general meeting held...

Zerion Team
|
April 8, 2021

Zerion Team in Numbers

An international and very diverse team is behind Zerion Pharma – a drug development company improving the formulation of poorly soluble drugs that are currently not reaching their therapeutical potential...

Zerion Team
|
March 12, 2021

ZERION Pharma expands its team with a Communications Specialist and a Formulation Technician

Ieva Jasiukenaite is joining ZERION’s commercial team as a Communications Specialist and Camila Belavi is joining ZERION’s R&D team as a Laboratory Technician. Both already joined ZERION during February and March...

Press Releases
|
February 9, 2021

Arla Foods Ingredients and ZERION announce agreement to secure supply of Lacprodan® BLG as key component in ZERION’s Dispersome® technology

(Copenhagen, February 9, 2021). Arla Foods Ingredients Group P/S (Arla), a subsidiary of Arla Foods amba, and drug formulation company Zerion ApS (ZERION) have entered into an agreement covering the supply of...

Zerion Team
|
January 4, 2021

ZERION expands its R&D team with Analytical Scientist and Scientific Director of Formulation to strengthen the company’s pipeline activities

Dr. Anis Arnous and Dr. Søren Vinter Søgaard will join ZERION’s R&D team as Analytical Scientist and Scientific Director...

Press Releases
|
November 12, 2020

ZERION appoints experienced CMC Director to join management team and drive the company’s drug development programs

PRESS RELEASE FOR IMMEDIATE RELEASE (Copenhagen, November 12, 2020). Danish drug formulation company ZERION announces the...

Zerion Team
|
October 23, 2020

ZERION appoints Jakob Dynnes Hansen as Chief Financial Officer and Mónica González Heredia as Director of Regulatory Affairs.

In addition to being responsible for financial operations, Jakob Dynnes Hansen will assume a key role in ZERION’s next financing round in the first half of 2021. As responsible for regulatory affairs, Mónica...

Press Releases
|
October 1, 2020

The Danish Innovation Fund has awarded ZERION a grant of DKK 1.9 million under its InnoBooster program

We are extremely grateful to receive this support from the Innovation Fund. This is the 3rd grant we have obtained from the Innovation Fund and their support has been instrumental in building ZERION as a company...